Business Wire

MI-EATON

7.3.2024 12:31:34 CET | Business Wire | Press release

Share
Eaton Receives Two Grants From the Czech Republic, Continues to Expand Mobility Capabilities and Resources in Europe, Middle East, and Africa

Intelligent power management company Eaton continues to expand its capabilities and resources in Europe, Middle East, and Africa (EMEA) with the recent announcements of two grants from the Czech Republic. The grants will fund participation in two innovative mobility projects, including assisting in the design and development of an electrified off-road truck and to develop and demonstrate a new power distribution unit (PDU) and DC/DC converter (200 kW) for hydrogen fuel cell powered trucks.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307921565/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s power distribution unit will be utilized in two electrified vehicle projects funded by grants from the Czech Republic. (Photo: Business Wire)

“We are continuously expanding our electrified vehicle capabilities in EMEA and forming meaningful partnerships with governments and automotive manufacturers and suppliers,” said Dr. Mihai Dorobantu, director, Technology Planning and Government Affairs, Eaton’s Mobility Group. “EMEA is an important growth region for electrified vehicles, and we are proud to help pave the way to an emissions-free future.”

One of the grants from the Czech Republic is to participate in a joint program with Tatra Trucks, a leading Czech truck manufacturer for both military and commercial applications, to produce a specialized off-road electrified truck, a prototype called the Battery Electric Tatra Truck with multi-speed Transmission (BETTT). Eaton’s contribution to the endeavor will be the integration of its power distribution unit (PDU) and award winning 4-speed transmission for medium- and heavy-duty electrified vehicles (EVs).

“We’re very excited to have been chosen to participate in this important project,” Dorobantu said. “Eaton strives to be at the forefront of innovation for all types of vehicles as the mobility industry continues its transition from internal combustion-powered vehicles to those with electrified drivetrains.”

Medium- and heavy-duty vehicle requirements are fundamentally different than passenger vehicles. Because larger vehicles, such as buses and trucks, are bigger and heavier than passenger vehicles, electrified versions require large electric motors and batteries, which add cost. However, many vehicles typically operate on routes with significant braking opportunities that generate power via regenerative braking, making electrification an attractive opportunity to reduce energy and improve performance simultaneously.

The 4-speed EV transmission, a part of Eaton’s eMobility portfolio of electrified vehicle components, solves the primary issue related to single-speed drives: contradictory requirements for high efficiency at top speeds and increased torque at launch and low speeds. It also promotes a more complete brake energy regeneration that reduces total energy consumption and battery needs.

Eaton’s PDUs connect the main battery power to the rest of the vehicle, similar to how a home service panel connects the main power source to each of the branch circuits in the house. While distributing power through the vehicle, the PDU, also known as junction boxes, or fuse boxes, also provides a safety function, protecting passengers and the vehicle’s expensive power electronics from short circuits and other electrical system faults.

“Eaton’s PDU leverages our extensive automotive experience and electrical expertise to ensure complete power protection with enhanced vehicle performance and efficiency,” Dorobantu said. “The BETTT project will allow us to gain knowledge from a specific application and demonstrate the performance benefits of our components on a system level.”

Eaton’s second grant is from the Czech government program DEFACTo (Definition and Demonstration of Fuel Cell BoP and DC/DC components) for a three-year program to develop and demonstrate a new PDU and DC/DC converter (200 kW) for hydrogen fuel cell powered trucks. In addition, an internal test bench with a fuel cell system (50 kW) will be set up at the Eaton European Innovation Center (EEIC) to expand and accelerate the company’s capabilities and developments in the field of hydrogen.

“To successfully complete this project, we are establishing a hydrogen fuel cell lab at our European Innovation Center in Prague to test out different fuel cell components, including air and hydrogen control systems, as well as working to integrate a fuel cell in a simulated vehicle or building,” Dorobantu said.

Learn more about Eaton’s EV transmission and PDU.

Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace and mobility markets. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.

Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240307921565/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye